Sandoz Group AG has entered into a strategic collaboration agreement with Henlius to develop and commercialize up to 10 biosimilar medicines.
Sandoz Group AG announced a strategic collaboration with Henlius to expand its biosimilar portfolio by up to 10 products.
The agreement broadens Sandoz's development pipeline in the biosimilars sector. Further financial terms and timelines regarding the individual compounds were not immediately disclosed in the announcement.
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
More from Helena Vásquez →